Catherine Parbutt
Overview
Explore the profile of Catherine Parbutt including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
29
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Slevin F, Hudson E, Boele F, Powell J, Noutch S, Borland M, et al.
BMJ Open
. 2025 Feb;
15(2):e097810.
PMID: 40010843
Introduction: Oligodendroglioma (ODG) is a rare type of brain tumour, typically diagnosed in younger adults and associated with prolonged survival following treatment. The current standard of care is maximal safe...
2.
Smith S, Green S, McNaught E, Graham C, Foy R, Loo Ow P, et al.
Ann Behav Med
. 2025 Jan;
59(1).
PMID: 39887069
Background: Adherence to adjuvant endocrine therapy (AET) in women with breast cancer is poor. Multicomponent intervention packages are needed to address adherence barriers. Optimizing these packages prior to definitive evaluation...
3.
Green S, Graham C, Collinson M, Loo Ow P, Hall L, French D, et al.
Transl Behav Med
. 2024 Dec;
15(1.
PMID: 39657026
Adherence to adjuvant endocrine therapy in women with breast cancer is low. We conducted a 24-1 fractional factorial pilot optimization trial to test four intervention components supporting medication adherence [text...
4.
Green S, Rousseau N, Hall L, French D, Graham C, Lloyd K, et al.
Prev Sci
. 2024 Jul;
25(7):1065-1078.
PMID: 39060840
Adjuvant endocrine therapy (AET) reduces mortality in early-stage breast cancer, but adherence is low. We developed a multicomponent intervention to support AET adherence comprising: text messages, information leaflet, acceptance and...
5.
Cracknell N, Parbutt C, Wong C, Ganijee T
J Oncol Pharm Pract
. 2024 Jun;
:10781552241259367.
PMID: 38835277
Introduction: The British Oncology Pharmacy Association (BOPA) Introduction to Oncology (ITO) course has run for over 20 years. The ITO course is provided free of charge to BOPA PAID members,...
6.
Hudson E, Noutch S, Webster J, Brown S, Boele F, Al-Salihi O, et al.
BMJ Open
. 2024 Mar;
14(3):e078926.
PMID: 38458809
Introduction: Glioblastoma (GBM) is the most common adult primary malignant brain tumour. The condition is incurable and, despite aggressive treatment at first presentation, almost all tumours recur after a median...
7.
Green S, Hall L, Rousseau N, French D, Graham C, Collinson M, et al.
NIHR Open Res
. 2023 Oct;
3:3.
PMID: 37881449
Background: The Refining and Optimising a behavioural intervention to Support Endocrine Therapy Adherence (ROSETA) programme has developed four intervention components aiming to improve medication adherence in women with early-stage breast...
8.
Green S, Hall L, French D, Rousseau N, Parbutt C, Walwyn R, et al.
Ann Behav Med
. 2023 Jul;
57(11):988-1000.
PMID: 37494669
Background: Adherence to adjuvant endocrine therapy (AET) is low in women with breast cancer. Negative beliefs about the necessity of AET and high concerns are barriers to adherence. Purpose: To...
9.
Green S, French D, Hall L, Bartlett Y, Rousseau N, Raine E, et al.
J Med Internet Res
. 2023 May;
25:e38073.
PMID: 37223964
Background: Adjuvant endocrine therapy (AET) reduces breast cancer recurrence and mortality in women with early-stage breast cancer. Unintentional nonadherence to AET is common (eg, forgetting to take medication). Forming habits...
10.
Smith S, Green S, Ellison R, Foy R, Graham C, Mason E, et al.
BMJ Open
. 2023 Feb;
13(2):e069971.
PMID: 36737093
Introduction: Women with breast cancer who do not adhere to adjuvant endocrine therapy (AET) have increased risks of mortality and recurrence. There are multiple barriers to AET adherence, including medication...